nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—ABCB1—kidney cancer	0.245	1	CbGaD
Naltrexone—UGT1A1—Pazopanib—kidney cancer	0.128	0.252	CbGbCtD
Naltrexone—UGT1A1—Erlotinib—kidney cancer	0.0911	0.18	CbGbCtD
Naltrexone—UGT1A1—Sorafenib—kidney cancer	0.0741	0.146	CbGbCtD
Naltrexone—ABCB1—Temsirolimus—kidney cancer	0.0482	0.0951	CbGbCtD
Naltrexone—ABCB1—Pazopanib—kidney cancer	0.0253	0.05	CbGbCtD
Naltrexone—ABCB1—Dactinomycin—kidney cancer	0.0232	0.0457	CbGbCtD
Naltrexone—ABCB1—Gemcitabine—kidney cancer	0.0183	0.0361	CbGbCtD
Naltrexone—ABCB1—Erlotinib—kidney cancer	0.0181	0.0357	CbGbCtD
Naltrexone—ABCB1—Paclitaxel—kidney cancer	0.0165	0.0326	CbGbCtD
Naltrexone—ABCB1—Sorafenib—kidney cancer	0.0147	0.029	CbGbCtD
Naltrexone—ABCB1—Vinblastine—kidney cancer	0.0145	0.0286	CbGbCtD
Naltrexone—ABCB1—Vincristine—kidney cancer	0.0143	0.0281	CbGbCtD
Naltrexone—ABCB1—Sunitinib—kidney cancer	0.0119	0.0235	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—kidney cancer	0.00892	0.0176	CbGbCtD
Naltrexone—UGT1A1—urine—kidney cancer	0.00244	0.433	CbGeAlD
Naltrexone—OPRD1—renal system—kidney cancer	0.000689	0.122	CbGeAlD
Naltrexone—OPRD1—kidney—kidney cancer	0.000666	0.118	CbGeAlD
Naltrexone—UGT1A1—renal system—kidney cancer	0.000597	0.106	CbGeAlD
Naltrexone—UGT1A1—kidney—kidney cancer	0.000578	0.102	CbGeAlD
Naltrexone—Hydromorphone—PTGS1—kidney cancer	0.000273	0.417	CrCbGaD
Naltrexone—ABCB1—nephron tubule—kidney cancer	0.000149	0.0265	CbGeAlD
Naltrexone—ABCB1—renal system—kidney cancer	0.000136	0.024	CbGeAlD
Naltrexone—Buprenorphine—ABCB1—kidney cancer	0.000135	0.206	CrCbGaD
Naltrexone—Naloxone—ABCB1—kidney cancer	0.000134	0.204	CrCbGaD
Naltrexone—ABCB1—kidney—kidney cancer	0.000131	0.0232	CbGeAlD
Naltrexone—ABCB1—cortex of kidney—kidney cancer	0.000128	0.0226	CbGeAlD
Naltrexone—ABCB1—gonad—kidney cancer	0.000122	0.0216	CbGeAlD
Naltrexone—Morphine—ABCB1—kidney cancer	0.000113	0.172	CrCbGaD
Naltrexone—Asthenia—Sunitinib—kidney cancer	8.7e-05	0.000369	CcSEcCtD
Naltrexone—Dyspnoea—Gemcitabine—kidney cancer	8.68e-05	0.000368	CcSEcCtD
Naltrexone—Nausea—Vinblastine—kidney cancer	8.66e-05	0.000367	CcSEcCtD
Naltrexone—Somnolence—Gemcitabine—kidney cancer	8.65e-05	0.000367	CcSEcCtD
Naltrexone—Convulsion—Paclitaxel—kidney cancer	8.65e-05	0.000367	CcSEcCtD
Naltrexone—Migraine—Doxorubicin—kidney cancer	8.63e-05	0.000366	CcSEcCtD
Naltrexone—Nausea—Everolimus—kidney cancer	8.62e-05	0.000366	CcSEcCtD
Naltrexone—Diarrhoea—Sorafenib—kidney cancer	8.62e-05	0.000366	CcSEcCtD
Naltrexone—Hypertension—Paclitaxel—kidney cancer	8.62e-05	0.000366	CcSEcCtD
Naltrexone—Pruritus—Sunitinib—kidney cancer	8.58e-05	0.000364	CcSEcCtD
Naltrexone—Angiopathy—Capecitabine—kidney cancer	8.54e-05	0.000362	CcSEcCtD
Naltrexone—Immune system disorder—Capecitabine—kidney cancer	8.5e-05	0.000361	CcSEcCtD
Naltrexone—Chest pain—Paclitaxel—kidney cancer	8.5e-05	0.000361	CcSEcCtD
Naltrexone—Myalgia—Paclitaxel—kidney cancer	8.5e-05	0.000361	CcSEcCtD
Naltrexone—Arthralgia—Paclitaxel—kidney cancer	8.5e-05	0.000361	CcSEcCtD
Naltrexone—Mediastinal disorder—Capecitabine—kidney cancer	8.48e-05	0.00036	CcSEcCtD
Naltrexone—Anxiety—Paclitaxel—kidney cancer	8.47e-05	0.000359	CcSEcCtD
Naltrexone—Face oedema—Doxorubicin—kidney cancer	8.47e-05	0.000359	CcSEcCtD
Naltrexone—Decreased appetite—Gemcitabine—kidney cancer	8.46e-05	0.000359	CcSEcCtD
Naltrexone—Hypersensitivity—Dactinomycin—kidney cancer	8.46e-05	0.000359	CcSEcCtD
Naltrexone—Chills—Capecitabine—kidney cancer	8.44e-05	0.000358	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	8.44e-05	0.000358	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Gemcitabine—kidney cancer	8.4e-05	0.000356	CcSEcCtD
Naltrexone—Discomfort—Paclitaxel—kidney cancer	8.4e-05	0.000356	CcSEcCtD
Naltrexone—Fatigue—Gemcitabine—kidney cancer	8.39e-05	0.000356	CcSEcCtD
Naltrexone—Gastrointestinal pain—Vincristine—kidney cancer	8.39e-05	0.000356	CcSEcCtD
Naltrexone—Dizziness—Sorafenib—kidney cancer	8.33e-05	0.000354	CcSEcCtD
Naltrexone—Pain—Gemcitabine—kidney cancer	8.32e-05	0.000353	CcSEcCtD
Naltrexone—Constipation—Gemcitabine—kidney cancer	8.32e-05	0.000353	CcSEcCtD
Naltrexone—Nausea—Erlotinib—kidney cancer	8.32e-05	0.000353	CcSEcCtD
Naltrexone—Alopecia—Capecitabine—kidney cancer	8.32e-05	0.000353	CcSEcCtD
Naltrexone—Dry mouth—Paclitaxel—kidney cancer	8.31e-05	0.000353	CcSEcCtD
Naltrexone—Diarrhoea—Sunitinib—kidney cancer	8.3e-05	0.000352	CcSEcCtD
Naltrexone—Mental disorder—Capecitabine—kidney cancer	8.24e-05	0.00035	CcSEcCtD
Naltrexone—Asthenia—Dactinomycin—kidney cancer	8.24e-05	0.000349	CcSEcCtD
Naltrexone—Confusional state—Paclitaxel—kidney cancer	8.22e-05	0.000348	CcSEcCtD
Naltrexone—Malnutrition—Capecitabine—kidney cancer	8.19e-05	0.000348	CcSEcCtD
Naltrexone—Dehydration—Doxorubicin—kidney cancer	8.15e-05	0.000346	CcSEcCtD
Naltrexone—Anaphylactic shock—Paclitaxel—kidney cancer	8.15e-05	0.000346	CcSEcCtD
Naltrexone—Oedema—Paclitaxel—kidney cancer	8.15e-05	0.000346	CcSEcCtD
Naltrexone—Body temperature increased—Vincristine—kidney cancer	8.11e-05	0.000344	CcSEcCtD
Naltrexone—Abdominal pain—Vincristine—kidney cancer	8.11e-05	0.000344	CcSEcCtD
Naltrexone—Infection—Paclitaxel—kidney cancer	8.09e-05	0.000343	CcSEcCtD
Naltrexone—Flatulence—Capecitabine—kidney cancer	8.07e-05	0.000342	CcSEcCtD
Naltrexone—Dysgeusia—Capecitabine—kidney cancer	8.02e-05	0.00034	CcSEcCtD
Naltrexone—Dizziness—Sunitinib—kidney cancer	8.02e-05	0.00034	CcSEcCtD
Naltrexone—Feeling abnormal—Gemcitabine—kidney cancer	8.02e-05	0.00034	CcSEcCtD
Naltrexone—Shock—Paclitaxel—kidney cancer	8.02e-05	0.00034	CcSEcCtD
Naltrexone—Vomiting—Sorafenib—kidney cancer	8.01e-05	0.00034	CcSEcCtD
Naltrexone—Abdominal pain upper—Doxorubicin—kidney cancer	8.01e-05	0.00034	CcSEcCtD
Naltrexone—Nervous system disorder—Paclitaxel—kidney cancer	7.99e-05	0.000339	CcSEcCtD
Naltrexone—Tachycardia—Paclitaxel—kidney cancer	7.95e-05	0.000337	CcSEcCtD
Naltrexone—Rash—Sorafenib—kidney cancer	7.95e-05	0.000337	CcSEcCtD
Naltrexone—Dermatitis—Sorafenib—kidney cancer	7.94e-05	0.000337	CcSEcCtD
Naltrexone—Back pain—Capecitabine—kidney cancer	7.92e-05	0.000336	CcSEcCtD
Naltrexone—Skin disorder—Paclitaxel—kidney cancer	7.91e-05	0.000336	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	7.9e-05	0.000335	CcSEcCtD
Naltrexone—Headache—Sorafenib—kidney cancer	7.9e-05	0.000335	CcSEcCtD
Naltrexone—Muscle spasms—Capecitabine—kidney cancer	7.88e-05	0.000334	CcSEcCtD
Naltrexone—Hyperhidrosis—Paclitaxel—kidney cancer	7.88e-05	0.000334	CcSEcCtD
Naltrexone—Diarrhoea—Dactinomycin—kidney cancer	7.86e-05	0.000333	CcSEcCtD
Naltrexone—Nasopharyngitis—Doxorubicin—kidney cancer	7.84e-05	0.000333	CcSEcCtD
Naltrexone—Anorexia—Paclitaxel—kidney cancer	7.77e-05	0.000329	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Doxorubicin—kidney cancer	7.73e-05	0.000328	CcSEcCtD
Naltrexone—Vision blurred—Capecitabine—kidney cancer	7.72e-05	0.000328	CcSEcCtD
Naltrexone—Vomiting—Sunitinib—kidney cancer	7.71e-05	0.000327	CcSEcCtD
Naltrexone—Body temperature increased—Gemcitabine—kidney cancer	7.69e-05	0.000326	CcSEcCtD
Naltrexone—Tremor—Capecitabine—kidney cancer	7.68e-05	0.000326	CcSEcCtD
Naltrexone—Rash—Sunitinib—kidney cancer	7.65e-05	0.000324	CcSEcCtD
Naltrexone—Dermatitis—Sunitinib—kidney cancer	7.64e-05	0.000324	CcSEcCtD
Naltrexone—Ill-defined disorder—Capecitabine—kidney cancer	7.6e-05	0.000322	CcSEcCtD
Naltrexone—Headache—Sunitinib—kidney cancer	7.6e-05	0.000322	CcSEcCtD
Naltrexone—Influenza—Doxorubicin—kidney cancer	7.58e-05	0.000321	CcSEcCtD
Naltrexone—Hypersensitivity—Vincristine—kidney cancer	7.56e-05	0.000321	CcSEcCtD
Naltrexone—Nausea—Sorafenib—kidney cancer	7.49e-05	0.000318	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.42e-05	0.000315	CcSEcCtD
Naltrexone—Malaise—Capecitabine—kidney cancer	7.39e-05	0.000313	CcSEcCtD
Naltrexone—Angina pectoris—Doxorubicin—kidney cancer	7.38e-05	0.000313	CcSEcCtD
Naltrexone—Insomnia—Paclitaxel—kidney cancer	7.37e-05	0.000313	CcSEcCtD
Naltrexone—Asthenia—Vincristine—kidney cancer	7.36e-05	0.000312	CcSEcCtD
Naltrexone—Syncope—Capecitabine—kidney cancer	7.35e-05	0.000312	CcSEcCtD
Naltrexone—Paraesthesia—Paclitaxel—kidney cancer	7.32e-05	0.00031	CcSEcCtD
Naltrexone—Vomiting—Dactinomycin—kidney cancer	7.3e-05	0.00031	CcSEcCtD
Naltrexone—Bronchitis—Doxorubicin—kidney cancer	7.29e-05	0.000309	CcSEcCtD
Naltrexone—Dyspnoea—Paclitaxel—kidney cancer	7.26e-05	0.000308	CcSEcCtD
Naltrexone—Somnolence—Paclitaxel—kidney cancer	7.24e-05	0.000307	CcSEcCtD
Naltrexone—Palpitations—Capecitabine—kidney cancer	7.24e-05	0.000307	CcSEcCtD
Naltrexone—Rash—Dactinomycin—kidney cancer	7.24e-05	0.000307	CcSEcCtD
Naltrexone—Nausea—Sunitinib—kidney cancer	7.2e-05	0.000306	CcSEcCtD
Naltrexone—Loss of consciousness—Capecitabine—kidney cancer	7.2e-05	0.000305	CcSEcCtD
Naltrexone—Cough—Capecitabine—kidney cancer	7.15e-05	0.000303	CcSEcCtD
Naltrexone—Decreased appetite—Paclitaxel—kidney cancer	7.08e-05	0.0003	CcSEcCtD
Naltrexone—Hypertension—Capecitabine—kidney cancer	7.07e-05	0.0003	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Doxorubicin—kidney cancer	7.04e-05	0.000299	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Paclitaxel—kidney cancer	7.03e-05	0.000298	CcSEcCtD
Naltrexone—Fatigue—Paclitaxel—kidney cancer	7.02e-05	0.000298	CcSEcCtD
Naltrexone—Diarrhoea—Vincristine—kidney cancer	7.02e-05	0.000298	CcSEcCtD
Naltrexone—Asthenia—Gemcitabine—kidney cancer	6.98e-05	0.000296	CcSEcCtD
Naltrexone—Chest pain—Capecitabine—kidney cancer	6.97e-05	0.000296	CcSEcCtD
Naltrexone—Myalgia—Capecitabine—kidney cancer	6.97e-05	0.000296	CcSEcCtD
Naltrexone—Arthralgia—Capecitabine—kidney cancer	6.97e-05	0.000296	CcSEcCtD
Naltrexone—Pain—Paclitaxel—kidney cancer	6.97e-05	0.000296	CcSEcCtD
Naltrexone—Constipation—Paclitaxel—kidney cancer	6.97e-05	0.000296	CcSEcCtD
Naltrexone—Anxiety—Capecitabine—kidney cancer	6.95e-05	0.000295	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	6.93e-05	0.000294	CcSEcCtD
Naltrexone—Weight increased—Doxorubicin—kidney cancer	6.9e-05	0.000293	CcSEcCtD
Naltrexone—Discomfort—Capecitabine—kidney cancer	6.89e-05	0.000292	CcSEcCtD
Naltrexone—Pruritus—Gemcitabine—kidney cancer	6.88e-05	0.000292	CcSEcCtD
Naltrexone—Weight decreased—Doxorubicin—kidney cancer	6.86e-05	0.000291	CcSEcCtD
Naltrexone—Dry mouth—Capecitabine—kidney cancer	6.82e-05	0.000289	CcSEcCtD
Naltrexone—Nausea—Dactinomycin—kidney cancer	6.82e-05	0.000289	CcSEcCtD
Naltrexone—Pneumonia—Doxorubicin—kidney cancer	6.8e-05	0.000288	CcSEcCtD
Naltrexone—Dizziness—Vincristine—kidney cancer	6.78e-05	0.000288	CcSEcCtD
Naltrexone—Infestation—Doxorubicin—kidney cancer	6.76e-05	0.000287	CcSEcCtD
Naltrexone—Infestation NOS—Doxorubicin—kidney cancer	6.76e-05	0.000287	CcSEcCtD
Naltrexone—Confusional state—Capecitabine—kidney cancer	6.74e-05	0.000286	CcSEcCtD
Naltrexone—Feeling abnormal—Paclitaxel—kidney cancer	6.71e-05	0.000285	CcSEcCtD
Naltrexone—Oedema—Capecitabine—kidney cancer	6.69e-05	0.000284	CcSEcCtD
Naltrexone—Gastrointestinal pain—Paclitaxel—kidney cancer	6.66e-05	0.000283	CcSEcCtD
Naltrexone—Diarrhoea—Gemcitabine—kidney cancer	6.66e-05	0.000282	CcSEcCtD
Naltrexone—Infection—Capecitabine—kidney cancer	6.64e-05	0.000282	CcSEcCtD
Naltrexone—Shock—Capecitabine—kidney cancer	6.58e-05	0.000279	CcSEcCtD
Naltrexone—Conjunctivitis—Doxorubicin—kidney cancer	6.57e-05	0.000279	CcSEcCtD
Naltrexone—Urinary tract infection—Doxorubicin—kidney cancer	6.57e-05	0.000279	CcSEcCtD
Naltrexone—Nervous system disorder—Capecitabine—kidney cancer	6.56e-05	0.000278	CcSEcCtD
Naltrexone—Tachycardia—Capecitabine—kidney cancer	6.53e-05	0.000277	CcSEcCtD
Naltrexone—Vomiting—Vincristine—kidney cancer	6.52e-05	0.000277	CcSEcCtD
Naltrexone—Skin disorder—Capecitabine—kidney cancer	6.49e-05	0.000275	CcSEcCtD
Naltrexone—Urticaria—Paclitaxel—kidney cancer	6.47e-05	0.000275	CcSEcCtD
Naltrexone—Rash—Vincristine—kidney cancer	6.47e-05	0.000274	CcSEcCtD
Naltrexone—Hyperhidrosis—Capecitabine—kidney cancer	6.46e-05	0.000274	CcSEcCtD
Naltrexone—Dermatitis—Vincristine—kidney cancer	6.46e-05	0.000274	CcSEcCtD
Naltrexone—Abdominal pain—Paclitaxel—kidney cancer	6.44e-05	0.000273	CcSEcCtD
Naltrexone—Body temperature increased—Paclitaxel—kidney cancer	6.44e-05	0.000273	CcSEcCtD
Naltrexone—Headache—Vincristine—kidney cancer	6.43e-05	0.000273	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—kidney cancer	6.39e-05	0.000271	CcSEcCtD
Naltrexone—Epistaxis—Doxorubicin—kidney cancer	6.37e-05	0.00027	CcSEcCtD
Naltrexone—Anorexia—Capecitabine—kidney cancer	6.37e-05	0.00027	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—kidney cancer	6.34e-05	0.000269	CcSEcCtD
Naltrexone—Vomiting—Gemcitabine—kidney cancer	6.19e-05	0.000262	CcSEcCtD
Naltrexone—Rash—Gemcitabine—kidney cancer	6.14e-05	0.00026	CcSEcCtD
Naltrexone—Dermatitis—Gemcitabine—kidney cancer	6.13e-05	0.00026	CcSEcCtD
Naltrexone—Headache—Gemcitabine—kidney cancer	6.1e-05	0.000259	CcSEcCtD
Naltrexone—Nausea—Vincristine—kidney cancer	6.09e-05	0.000258	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Capecitabine—kidney cancer	6.09e-05	0.000258	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—kidney cancer	6.07e-05	0.000257	CcSEcCtD
Naltrexone—Insomnia—Capecitabine—kidney cancer	6.05e-05	0.000257	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—kidney cancer	6.02e-05	0.000255	CcSEcCtD
Naltrexone—Paraesthesia—Capecitabine—kidney cancer	6e-05	0.000255	CcSEcCtD
Naltrexone—Hypersensitivity—Paclitaxel—kidney cancer	6e-05	0.000255	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—kidney cancer	5.96e-05	0.000253	CcSEcCtD
Naltrexone—Dyspnoea—Capecitabine—kidney cancer	5.96e-05	0.000253	CcSEcCtD
Naltrexone—Asthenia—Paclitaxel—kidney cancer	5.85e-05	0.000248	CcSEcCtD
Naltrexone—Decreased appetite—Capecitabine—kidney cancer	5.81e-05	0.000247	CcSEcCtD
Naltrexone—Nausea—Gemcitabine—kidney cancer	5.78e-05	0.000245	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Capecitabine—kidney cancer	5.77e-05	0.000245	CcSEcCtD
Naltrexone—Fatigue—Capecitabine—kidney cancer	5.76e-05	0.000245	CcSEcCtD
Naltrexone—Pruritus—Paclitaxel—kidney cancer	5.76e-05	0.000245	CcSEcCtD
Naltrexone—Constipation—Capecitabine—kidney cancer	5.72e-05	0.000243	CcSEcCtD
Naltrexone—Pain—Capecitabine—kidney cancer	5.72e-05	0.000243	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—kidney cancer	5.67e-05	0.00024	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—kidney cancer	5.66e-05	0.00024	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—kidney cancer	5.63e-05	0.000239	CcSEcCtD
Naltrexone—Diarrhoea—Paclitaxel—kidney cancer	5.57e-05	0.000236	CcSEcCtD
Naltrexone—Feeling abnormal—Capecitabine—kidney cancer	5.51e-05	0.000234	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—kidney cancer	5.5e-05	0.000233	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—kidney cancer	5.48e-05	0.000232	CcSEcCtD
Naltrexone—Gastrointestinal pain—Capecitabine—kidney cancer	5.47e-05	0.000232	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—kidney cancer	5.47e-05	0.000232	CcSEcCtD
Naltrexone—Chills—Doxorubicin—kidney cancer	5.44e-05	0.000231	CcSEcCtD
Naltrexone—Dizziness—Paclitaxel—kidney cancer	5.39e-05	0.000229	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—kidney cancer	5.36e-05	0.000227	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—kidney cancer	5.31e-05	0.000225	CcSEcCtD
Naltrexone—Urticaria—Capecitabine—kidney cancer	5.31e-05	0.000225	CcSEcCtD
Naltrexone—Body temperature increased—Capecitabine—kidney cancer	5.29e-05	0.000224	CcSEcCtD
Naltrexone—Abdominal pain—Capecitabine—kidney cancer	5.29e-05	0.000224	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—kidney cancer	5.28e-05	0.000224	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—kidney cancer	5.2e-05	0.000221	CcSEcCtD
Naltrexone—Tension—Doxorubicin—kidney cancer	5.18e-05	0.00022	CcSEcCtD
Naltrexone—Vomiting—Paclitaxel—kidney cancer	5.18e-05	0.00022	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—kidney cancer	5.17e-05	0.000219	CcSEcCtD
Naltrexone—Rash—Paclitaxel—kidney cancer	5.14e-05	0.000218	CcSEcCtD
Naltrexone—Dermatitis—Paclitaxel—kidney cancer	5.13e-05	0.000218	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—kidney cancer	5.13e-05	0.000218	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—kidney cancer	5.11e-05	0.000217	CcSEcCtD
Naltrexone—Headache—Paclitaxel—kidney cancer	5.1e-05	0.000217	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—kidney cancer	5.08e-05	0.000215	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—kidney cancer	4.98e-05	0.000211	CcSEcCtD
Naltrexone—Hypersensitivity—Capecitabine—kidney cancer	4.93e-05	0.000209	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—kidney cancer	4.9e-05	0.000208	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—kidney cancer	4.85e-05	0.000206	CcSEcCtD
Naltrexone—Nausea—Paclitaxel—kidney cancer	4.84e-05	0.000205	CcSEcCtD
Naltrexone—Asthenia—Capecitabine—kidney cancer	4.8e-05	0.000203	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—kidney cancer	4.76e-05	0.000202	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—kidney cancer	4.74e-05	0.000201	CcSEcCtD
Naltrexone—Pruritus—Capecitabine—kidney cancer	4.73e-05	0.000201	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—kidney cancer	4.67e-05	0.000198	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—kidney cancer	4.64e-05	0.000197	CcSEcCtD
Naltrexone—Cough—Doxorubicin—kidney cancer	4.61e-05	0.000195	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—kidney cancer	4.58e-05	0.000194	CcSEcCtD
Naltrexone—Diarrhoea—Capecitabine—kidney cancer	4.57e-05	0.000194	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—kidney cancer	4.56e-05	0.000193	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—kidney cancer	4.5e-05	0.000191	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—kidney cancer	4.5e-05	0.000191	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—kidney cancer	4.5e-05	0.000191	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—kidney cancer	4.48e-05	0.00019	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.46e-05	0.000189	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—kidney cancer	4.44e-05	0.000188	CcSEcCtD
Naltrexone—Dizziness—Capecitabine—kidney cancer	4.42e-05	0.000188	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—kidney cancer	4.4e-05	0.000187	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—kidney cancer	4.35e-05	0.000184	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—kidney cancer	4.31e-05	0.000183	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—kidney cancer	4.31e-05	0.000183	CcSEcCtD
Naltrexone—Infection—Doxorubicin—kidney cancer	4.28e-05	0.000182	CcSEcCtD
Naltrexone—Vomiting—Capecitabine—kidney cancer	4.25e-05	0.00018	CcSEcCtD
Naltrexone—Shock—Doxorubicin—kidney cancer	4.24e-05	0.00018	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—kidney cancer	4.23e-05	0.000179	CcSEcCtD
Naltrexone—Rash—Capecitabine—kidney cancer	4.22e-05	0.000179	CcSEcCtD
Naltrexone—Dermatitis—Capecitabine—kidney cancer	4.21e-05	0.000179	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—kidney cancer	4.21e-05	0.000178	CcSEcCtD
Naltrexone—Headache—Capecitabine—kidney cancer	4.19e-05	0.000178	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—kidney cancer	4.19e-05	0.000178	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—kidney cancer	4.17e-05	0.000177	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—kidney cancer	4.11e-05	0.000174	CcSEcCtD
Naltrexone—Nausea—Capecitabine—kidney cancer	3.97e-05	0.000168	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.93e-05	0.000167	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—kidney cancer	3.9e-05	0.000165	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—kidney cancer	3.87e-05	0.000164	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—kidney cancer	3.84e-05	0.000163	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—kidney cancer	3.83e-05	0.000163	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—kidney cancer	3.75e-05	0.000159	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.72e-05	0.000158	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—kidney cancer	3.72e-05	0.000158	CcSEcCtD
Naltrexone—Pain—Doxorubicin—kidney cancer	3.69e-05	0.000156	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—kidney cancer	3.69e-05	0.000156	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—kidney cancer	3.55e-05	0.000151	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—kidney cancer	3.52e-05	0.000149	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—kidney cancer	3.42e-05	0.000145	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—kidney cancer	3.41e-05	0.000145	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—kidney cancer	3.41e-05	0.000145	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—kidney cancer	3.18e-05	0.000135	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—kidney cancer	3.09e-05	0.000131	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—kidney cancer	3.05e-05	0.000129	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—kidney cancer	2.95e-05	0.000125	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—kidney cancer	2.85e-05	0.000121	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—kidney cancer	2.74e-05	0.000116	CcSEcCtD
Naltrexone—Rash—Doxorubicin—kidney cancer	2.72e-05	0.000115	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—kidney cancer	2.71e-05	0.000115	CcSEcCtD
Naltrexone—Headache—Doxorubicin—kidney cancer	2.7e-05	0.000115	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—kidney cancer	2.56e-05	0.000109	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—SFRP2—kidney cancer	1.11e-05	0.00179	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ST3GAL2—kidney cancer	1.1e-05	0.00176	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—ANXA1—kidney cancer	1.08e-05	0.00174	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALDH1A1—kidney cancer	1.07e-05	0.00172	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—ITPR2—kidney cancer	1.05e-05	0.00169	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	1.05e-05	0.00169	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL2—kidney cancer	1.05e-05	0.00169	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—ANXA1—kidney cancer	1.04e-05	0.00168	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	1.04e-05	0.00168	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—POMC—kidney cancer	1.03e-05	0.00166	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	1.03e-05	0.00165	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PGK1—kidney cancer	1.03e-05	0.00165	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SLC5A3—kidney cancer	1.03e-05	0.00165	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—LDHB—kidney cancer	1.01e-05	0.00162	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ATP7B—kidney cancer	1.01e-05	0.00162	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	1.01e-05	0.00162	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ANXA2—kidney cancer	1.01e-05	0.00162	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	1.01e-05	0.00162	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SFRP2—kidney cancer	9.76e-06	0.00157	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CER1—kidney cancer	9.7e-06	0.00156	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GPC3—kidney cancer	9.7e-06	0.00156	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ITPR2—kidney cancer	9.57e-06	0.00154	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—ANXA1—kidney cancer	9.49e-06	0.00152	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—POMC—kidney cancer	9.06e-06	0.00146	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ACY1—kidney cancer	8.98e-06	0.00144	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP2—kidney cancer	8.97e-06	0.00144	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKAP13—kidney cancer	8.97e-06	0.00144	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—VEGFA—kidney cancer	8.91e-06	0.00143	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—ANXA1—kidney cancer	8.83e-06	0.00142	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CA9—kidney cancer	8.74e-06	0.00141	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SFRP2—kidney cancer	8.25e-06	0.00133	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GRB7—kidney cancer	8.2e-06	0.00132	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ANXA1—kidney cancer	8.02e-06	0.00129	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP2—kidney cancer	7.86e-06	0.00126	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKAP13—kidney cancer	7.86e-06	0.00126	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—POMC—kidney cancer	7.65e-06	0.00123	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PDHB—kidney cancer	7.64e-06	0.00123	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ITPR2—kidney cancer	7.63e-06	0.00123	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CRABP1—kidney cancer	7.43e-06	0.0012	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	7.35e-06	0.00118	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GRB7—kidney cancer	7.19e-06	0.00116	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CCBL1—kidney cancer	7.18e-06	0.00115	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CTNNA1—kidney cancer	6.91e-06	0.00111	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ITPR2—kidney cancer	6.91e-06	0.00111	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EIF4EBP1—kidney cancer	6.87e-06	0.00111	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HSPB1—kidney cancer	6.87e-06	0.00111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ITPR2—kidney cancer	6.69e-06	0.00108	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP2—kidney cancer	6.65e-06	0.00107	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKAP13—kidney cancer	6.65e-06	0.00107	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TSC1—kidney cancer	6.39e-06	0.00103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ANXA1—kidney cancer	6.39e-06	0.00103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PSMD7—kidney cancer	6.39e-06	0.00103	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ACHE—kidney cancer	6.3e-06	0.00101	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTT1—kidney cancer	6.3e-06	0.00101	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPAT—kidney cancer	6.22e-06	0.001	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GLIPR1—kidney cancer	6.22e-06	0.001	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FLT1—kidney cancer	6.19e-06	0.000995	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GRB7—kidney cancer	6.08e-06	0.000977	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CTNNA1—kidney cancer	6.06e-06	0.000975	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HSPB1—kidney cancer	6.03e-06	0.000969	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EIF4EBP1—kidney cancer	6.03e-06	0.000969	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SCARB1—kidney cancer	5.97e-06	0.000959	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS1—kidney cancer	5.91e-06	0.000949	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—POMC—kidney cancer	5.84e-06	0.000938	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PSMD7—kidney cancer	5.79e-06	0.000931	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—FH—kidney cancer	5.79e-06	0.00093	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APRT—kidney cancer	5.79e-06	0.00093	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	5.77e-06	0.000928	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PAK1—kidney cancer	5.74e-06	0.000922	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JUNB—kidney cancer	5.74e-06	0.000922	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	5.71e-06	0.000918	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ITPR2—kidney cancer	5.65e-06	0.000909	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PSMD7—kidney cancer	5.6e-06	0.000901	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TSC1—kidney cancer	5.6e-06	0.000901	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ANXA1—kidney cancer	5.6e-06	0.000901	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	5.58e-06	0.000898	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—BCHE—kidney cancer	5.49e-06	0.000883	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPC3—kidney cancer	5.44e-06	0.000875	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FLT1—kidney cancer	5.43e-06	0.000872	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SLC5A5—kidney cancer	5.42e-06	0.000872	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	5.31e-06	0.000854	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—POMC—kidney cancer	5.3e-06	0.000852	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CA2—kidney cancer	5.29e-06	0.000851	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	5.29e-06	0.00085	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SLC2A1—kidney cancer	5.24e-06	0.000842	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALAD—kidney cancer	5.16e-06	0.000829	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	5.13e-06	0.000825	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CTNNA1—kidney cancer	5.12e-06	0.000824	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—POMC—kidney cancer	5.12e-06	0.000823	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EIF4EBP1—kidney cancer	5.09e-06	0.000819	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HSPB1—kidney cancer	5.09e-06	0.000819	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	5.04e-06	0.000811	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ST3GAL2—kidney cancer	5.03e-06	0.000809	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	5.03e-06	0.000809	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PAK1—kidney cancer	5.03e-06	0.000809	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JUNB—kidney cancer	5.03e-06	0.000809	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	5e-06	0.000803	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDH1A1—kidney cancer	4.92e-06	0.000791	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	4.87e-06	0.000783	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TSC1—kidney cancer	4.74e-06	0.000761	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PSMD7—kidney cancer	4.74e-06	0.000761	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ANXA1—kidney cancer	4.74e-06	0.000761	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PGK1—kidney cancer	4.72e-06	0.000758	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC5A3—kidney cancer	4.72e-06	0.000758	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF2—kidney cancer	4.69e-06	0.000754	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN2B—kidney cancer	4.67e-06	0.000751	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—POMC—kidney cancer	4.65e-06	0.000747	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LDHB—kidney cancer	4.63e-06	0.000744	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FLT1—kidney cancer	4.59e-06	0.000737	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1R—kidney cancer	4.54e-06	0.000729	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	4.4e-06	0.000707	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—RAF1—kidney cancer	4.37e-06	0.000703	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTP1—kidney cancer	4.37e-06	0.000702	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—POMC—kidney cancer	4.33e-06	0.000695	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL2—kidney cancer	4.31e-06	0.000694	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JUNB—kidney cancer	4.25e-06	0.000684	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PAK1—kidney cancer	4.25e-06	0.000684	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	4.16e-06	0.000669	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ABCB1—kidney cancer	4.14e-06	0.000665	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF2—kidney cancer	4.11e-06	0.000661	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN2B—kidney cancer	4.1e-06	0.000658	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	4.05e-06	0.000651	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTM1—kidney cancer	4.01e-06	0.000645	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CA9—kidney cancer	4.01e-06	0.000645	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1R—kidney cancer	3.98e-06	0.000639	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	3.96e-06	0.000636	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—POMC—kidney cancer	3.93e-06	0.000631	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2—kidney cancer	3.92e-06	0.00063	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—RAF1—kidney cancer	3.83e-06	0.000616	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP1A1—kidney cancer	3.81e-06	0.000612	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2—kidney cancer	3.78e-06	0.000608	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	3.74e-06	0.000601	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HIF1A—kidney cancer	3.73e-06	0.0006	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TSC2—kidney cancer	3.72e-06	0.000599	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KDR—kidney cancer	3.57e-06	0.000574	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF2—kidney cancer	3.48e-06	0.000559	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN2B—kidney cancer	3.46e-06	0.000556	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—kidney cancer	3.44e-06	0.000552	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	3.44e-06	0.000552	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CRABP1—kidney cancer	3.41e-06	0.000548	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1R—kidney cancer	3.36e-06	0.00054	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	3.32e-06	0.000534	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APC—kidney cancer	3.29e-06	0.000529	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KIT—kidney cancer	3.29e-06	0.000529	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—kidney cancer	3.27e-06	0.000526	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TSC2—kidney cancer	3.27e-06	0.000525	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RAF1—kidney cancer	3.24e-06	0.000521	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—kidney cancer	3.2e-06	0.000514	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ITPR2—kidney cancer	3.17e-06	0.00051	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK3—kidney cancer	3.15e-06	0.000506	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—POMC—kidney cancer	3.13e-06	0.000503	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—kidney cancer	3.13e-06	0.000503	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BRAF—kidney cancer	3.09e-06	0.000497	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK1—kidney cancer	3e-06	0.000482	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—kidney cancer	2.9e-06	0.000467	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ACHE—kidney cancer	2.89e-06	0.000465	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—kidney cancer	2.89e-06	0.000465	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KIT—kidney cancer	2.88e-06	0.000464	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APC—kidney cancer	2.88e-06	0.000464	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—kidney cancer	2.86e-06	0.00046	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—POMC—kidney cancer	2.84e-06	0.000456	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—kidney cancer	2.83e-06	0.000455	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—kidney cancer	2.77e-06	0.000445	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK3—kidney cancer	2.76e-06	0.000444	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TSC2—kidney cancer	2.76e-06	0.000444	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—POMC—kidney cancer	2.75e-06	0.000441	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SCARB1—kidney cancer	2.74e-06	0.00044	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BRAF—kidney cancer	2.71e-06	0.000436	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS1—kidney cancer	2.71e-06	0.000436	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PSMD7—kidney cancer	2.66e-06	0.000427	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—kidney cancer	2.65e-06	0.000425	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK1—kidney cancer	2.63e-06	0.000423	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—kidney cancer	2.6e-06	0.000418	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAF1—kidney cancer	2.58e-06	0.000415	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RELA—kidney cancer	2.57e-06	0.000413	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ERBB2—kidney cancer	2.55e-06	0.000411	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MTOR—kidney cancer	2.52e-06	0.000405	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—BCHE—kidney cancer	2.52e-06	0.000405	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—kidney cancer	2.51e-06	0.000404	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC5A5—kidney cancer	2.49e-06	0.0004	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—kidney cancer	2.48e-06	0.000399	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KIT—kidney cancer	2.44e-06	0.000392	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APC—kidney cancer	2.44e-06	0.000392	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC2A1—kidney cancer	2.4e-06	0.000386	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1B—kidney cancer	2.37e-06	0.00038	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK3—kidney cancer	2.33e-06	0.000375	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—POMC—kidney cancer	2.32e-06	0.000373	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—kidney cancer	2.31e-06	0.000372	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	2.29e-06	0.000368	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BRAF—kidney cancer	2.29e-06	0.000368	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—kidney cancer	2.28e-06	0.000367	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAF1—kidney cancer	2.26e-06	0.000364	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—kidney cancer	2.26e-06	0.000364	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—kidney cancer	2.26e-06	0.000363	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RELA—kidney cancer	2.25e-06	0.000362	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JUN—kidney cancer	2.25e-06	0.000362	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB2—kidney cancer	2.24e-06	0.00036	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CTNNB1—kidney cancer	2.23e-06	0.000359	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK1—kidney cancer	2.22e-06	0.000357	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MTOR—kidney cancer	2.21e-06	0.000355	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTEN—kidney cancer	2.18e-06	0.00035	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—kidney cancer	2.12e-06	0.000341	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—kidney cancer	2.1e-06	0.000337	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1B—kidney cancer	2.07e-06	0.000333	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—kidney cancer	2.03e-06	0.000326	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—kidney cancer	2e-06	0.000322	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—kidney cancer	1.98e-06	0.000318	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JUN—kidney cancer	1.97e-06	0.000317	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTEN—kidney cancer	1.97e-06	0.000317	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—kidney cancer	1.97e-06	0.000316	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CTNNB1—kidney cancer	1.96e-06	0.000315	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—kidney cancer	1.93e-06	0.00031	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAF1—kidney cancer	1.91e-06	0.000308	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTEN—kidney cancer	1.91e-06	0.000307	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RELA—kidney cancer	1.9e-06	0.000306	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB2—kidney cancer	1.89e-06	0.000304	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MTOR—kidney cancer	1.87e-06	0.0003	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK3—kidney cancer	1.86e-06	0.000299	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—kidney cancer	1.84e-06	0.000296	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—kidney cancer	1.81e-06	0.000291	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK1—kidney cancer	1.77e-06	0.000285	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1B—kidney cancer	1.75e-06	0.000282	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1A1—kidney cancer	1.75e-06	0.000281	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—kidney cancer	1.72e-06	0.000277	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—kidney cancer	1.72e-06	0.000276	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—kidney cancer	1.67e-06	0.000269	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—kidney cancer	1.67e-06	0.000269	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JUN—kidney cancer	1.67e-06	0.000268	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CTNNB1—kidney cancer	1.66e-06	0.000266	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK3—kidney cancer	1.63e-06	0.000262	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTEN—kidney cancer	1.61e-06	0.000259	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—kidney cancer	1.59e-06	0.000255	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK1—kidney cancer	1.55e-06	0.00025	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—kidney cancer	1.54e-06	0.000247	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—kidney cancer	1.49e-06	0.000239	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—kidney cancer	1.47e-06	0.000236	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—kidney cancer	1.46e-06	0.000234	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—kidney cancer	1.39e-06	0.000224	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK3—kidney cancer	1.38e-06	0.000222	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—kidney cancer	1.35e-06	0.000217	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—kidney cancer	1.34e-06	0.000216	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK1—kidney cancer	1.31e-06	0.000211	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—kidney cancer	1.3e-06	0.00021	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—POMC—kidney cancer	1.3e-06	0.000209	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—kidney cancer	1.24e-06	0.000199	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—kidney cancer	1.14e-06	0.000183	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—kidney cancer	1.1e-06	0.000177	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—kidney cancer	1.04e-06	0.000167	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTEN—kidney cancer	9.06e-07	0.000146	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—kidney cancer	6.39e-07	0.000103	CbGpPWpGaD
